Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.
Back
Dr Ho on the Investigation of Ozuriftamab Vedotin in HPV-Associated OPSCC
Dr Ho on the Investigation of Ozuriftamab Vedotin in HPV-Associated OPSCC
Episodes
All
All
Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.
Alan L. Ho, MD, PhD, discusses next steps for the evaluation of Oz-V in OPSCC based on its phase 2 efficacy in patients with treatment-refractory disease.
Alan L. Ho, MD, PhD, discusses an upcoming phase 3 trial evaluating Oz-V in OPSCC and key aspects of its design.
Advertisement
Advertisement
Trending on OncLive
1
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
Five Under 5: Top Oncology Videos for the Week of 8/9
4
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
5